Ely Gold Royalties (CVE:ELY) Sets New 12-Month High at $1.27

Share on StockTwits

Shares of Ely Gold Royalties Inc (CVE:ELY) reached a new 52-week high during trading on Friday . The stock traded as high as C$1.27 and last traded at C$1.24, with a volume of 881406 shares. The stock had previously closed at C$1.19.

The company has a market cap of $103.42 million and a price-to-earnings ratio of -79.38. The company’s 50 day moving average price is C$0.83 and its 200 day moving average price is C$0.62. The company has a debt-to-equity ratio of 12.08, a quick ratio of 2.94 and a current ratio of 2.99.

In related news, Director William Morris Sheriff sold 32,000 shares of the company’s stock in a transaction on Thursday, April 16th. The shares were sold at an average price of C$0.81, for a total value of C$25,920.00. Following the completion of the sale, the director now directly owns 258,000 shares in the company, valued at C$208,980.

About Ely Gold Royalties (CVE:ELY)

Ely Gold Royalties Inc, an exploration stage natural resource company, engages in the evaluation, acquisition, exploration, and development of natural resource projects in North America. It primarily explores for gold and precious metal deposits. Ely Gold Royalties Inc has a portfolio of 31 deeded royalties and 19 optioned properties.

Featured Story: Terms to Better Understand Call Options

Receive News & Ratings for Ely Gold Royalties Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ely Gold Royalties and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Insider Selling: Onespan Inc  Director Sells $1,056,000.00 in Stock
Insider Selling: Onespan Inc Director Sells $1,056,000.00 in Stock
Hurricane Energy  Stock Rating Lowered by Morgan Stanley
Hurricane Energy Stock Rating Lowered by Morgan Stanley
Zacks Investment Research Downgrades Clinigen Group  to Sell
Zacks Investment Research Downgrades Clinigen Group to Sell
Capgemini’s  “Buy” Rating Reiterated at Societe Generale
Capgemini’s “Buy” Rating Reiterated at Societe Generale
Canadian Western Bank  PT Raised to $23.00
Canadian Western Bank PT Raised to $23.00
Basilea Pharmaceutica  Stock Rating Upgraded by Zacks Investment Research
Basilea Pharmaceutica Stock Rating Upgraded by Zacks Investment Research


 
© 2006-2020 Zolmax.